It is now generally accepted that atherosclerosis is an inflammatory/immune disease triggered by LDL accumulation in the artery wall. When discovering T cells and the molecular components of a cellular immune response, we proposed that atherosclerosis is an inflammatory process with an autoimmune component. This notion was met with general skepticism but has gained support from experimental and clinical studies. Here we describe some of the early studies that helped developing this concept.
T hirty years ago the pathogenesis of atherosclerosis was still poorly understood. Although it was evident that hypercholesterolemia is a major risk factor and that cholesterol accumulates in atherosclerotic lesions, the cell biology of atherosclerosis remained a puzzle. It was speculated that the arterial lesions formed as a reaction to mechanical or chemical injury, developed from mural thrombi, or alternatively represented a hyperplastic or neoplastic process involving altered smooth muscle cells (SMCs). According to a prevailing theory, a proliferative expansion of SMCs from the media to the intima was driven by growth factors released from platelets. The subsequent deposition of both lipid and collagen would then result in the formation of local fibrous plaques.
Lipid-laden foam cells were commonly detected in both experimental and human plaques. Some of these foam cells showed ultrastructural characteristics of SMCs, but in the early 1980s it became obvious that many of them shared histochemical and morphological features of macrophages suggesting a monocytic origin. Because monocyte-derived macrophages play major roles in the immune system, it would seem obvious that the presence of such cells would point to an immune component of atherosclerosis. The idea of an involvement of immune cells in the pathogenesis of atherosclerosis had in fact been raised already by Virchow in 1856. However, more than 125 years after his report, the presence of lymphocyte-like infiltrates were still reported only incidentally in the literature and until the late 1980s immunologic events in atherosclerosis were ignored by most investigators.
A major reason for this ignorance was the difficulty to identify immunocompetent cells. Morphological changes that occur during differentiation or activation are not specific to any one of the major lymphocyte subsets, namely T cells, B cells, and natural killer cells. The contribution of blood-borne cells in atherosclerosis therefore remained unclear until the advent of the monoclonal antibody technology. The development of monoclonal antibodies against cell type-specific molecules on leukocytes, so-called cluster of differentiation (CD) antigens, thus opened up new and unique opportunities for identifying immune cells and determine their distribution in the atherosclerotic plaque.
In the early 1980s, when we worked in the Departments of Histology and Clinical Chemistry at Goteborg University, we designed a new project in collaboration with Dr Jan Holm, chief of vascular surgery at Sahlgrenska Hospital in Goteborg, Sweden. We decided to map the human atherosclerotic plaque by using CD-defined monoclonal antibodies. Fresh atherosclerotic tissue was collected from patients undergoing carotid endarterectomy, a procedure which removes the plaque in toto. Thin cryostat sections of plaque tissue were assayed using monoclonal antibodies to CD antigens of monocytes, T cells, CD4ϩ and CD8ϩ T cell subsets, B cells, and natural killer cells. Not unexpectedly, most of the large lipid-laden foam cells in the lipid-rich core were shown to be monocyte-derived macrophages. Many of these cells expressed HLA-DR, an MHC class II protein needed for antigen presentation to CD4ϩ T cells ( Figure 1 ). The abundant HLA-DR expression in the plaque immediately suggested to us that an active immune-inflammatory reaction may be part of the atherosclerotic process. A paper proposing such a reaction was immediately rejected by Nature but could be published, after lengthy revisions, in the Journal of Clinical Investigation 1985. 1 This was the first report suggesting a cellular immune response in atherosclerosis.
Because macrophages and MHC class II molecules were present in lesions, we expected to find T cells. Indeed, they were abundant in the shoulder and fibrous cap regions where they constituted around 20% of all cells. Interestingly, CD8ϩ T cells were almost as frequent as CD4ϩ T cells in peripheral parts of plaques; this differs from the CD4/CD8 ratio normally seen in blood or other peripheral lymphoid tissue. Neutrophils, identified by morphological and histochemical criteria, were conspicuously absent indicating that the inflammation had developed into a chronic condition. In addition, B cells were very sparse suggesting a predominantly cellular rather than humoral immune response. The presence of a T cell dominance was confirmed when cells were isolated from the plaques by collagenase digestion and analyzed by functional criteria. Because the recovery of cells was low, data from these experiments should however be regarded as mainly qualitative. When indirect methods to distinguish T cells and B cells were used, such as B cell-specific affinity for antiimmunoglobulins and "rosetting" of T cells with sheep erythrocytes (which depends on CD2 binding), no B cells were detected whereas 5% of the cells were T cells. These findings were reported in the March 1986 issue of Arteriosclerosis (now ATVB). 2 Our identification of T cells obtained support when Gown et al, toward the end of that year, reported their finding of small round cells staining positive for the leukocyte common antigen, cells that they interpreted as lymphocytes. 3 Two-thirds of isolated plaque T cells reacted with a monoclonal antibody against HLA-DR, indicating that they were in an activated state ( Figure 2 ). This was indeed an inspiring finding and the first time that immune activation was demonstrated in atherosclerosis. Analysis of cell isolates and cryostat sections using antibodies against other activation markers confirmed these primary data and showed that a substantial portion of plaque T cells are in a state of late or chronic activation. 4 MHC class II molecules (in humans HLA-DR, -DQ, -DP) are found predominantly on the surface of immunocompetent cells; activated T cells, mature B cells, dendritic cells, and subpopulations of monocytes/macrophages. As mentioned, they play a key role in cellular immunity and are required for antigen presentation to T cells, ie, an antigen can only be recognized by the T cell if it is displayed in combination with MHC class II molecules on the surface of an antigen-presenting cell. In the human carotid plaque, the majority of cells expressed HLA-DR, thus supporting the presence of an ongoing local immune response. 1 However, a substantial portion of the HLA-DR-positive cells in the plaque were identified as SMCs. This was obviously a phenomenon associated with the disease because medial SMCs were invariably DR-negative and SMCs from nonatherosclerotic intima rarely expressed HLA-DR.
In the mid 1980s, there were other reports about "aberrant" expression of class II molecules by a variety of cell types, in certain normal tissues but also in autoimmune diseases including thyroiditis, rheumatoid arthritis, and type 1 diabetes. [5] [6] [7] Thorsby and colleagues reported, in 1980, that vascular endothelial cells can activate T cells by presenting their HLA-DR antigen, 8 thus identifying a link between the immune system and the vessel wall. It became evident that T cells played an important role in the regulation of aberrant HLA-DR expression, and in 1983 Pober et al could demonstrate that the T cell product interferon-(IFN)-␥ was a potent inducer of class II molecules on endothelial cells in culture. 9 Some years later, we reported that recombinant IFN-␥ induced HLA-DR also in aortic SMCs. 10 We were also able to demonstrate that the expression of MHC class II molecules was induced in vivo after arterial injury in a rat model of vascular injury. 10 The finding of MHC molecules in the repair process after vascular injury prompted us to find out whether immunomodulators could prevent restenosis. We administered the T cell selective immunomodulator, cyclosporine A, to rats after balloon injury and found that this drug not only reduces local MHC class II expression but also attenuates SMC proliferation and inhibits the formation of arterial lesions. 11 Subsequent studies showed that cyclosporine A can directly inhibit SMC proliferation, an effect that adds to its immunomodulatory action. 12 Although we were unsuccessful in our attempts to interest the pharmaceutical industry to use this principle for developing therapy against restenosis, others using the next generation of T cell immunomodulator, rapamycin/sirolimus were more successful. 13 Immunomodulator coated stents are now commonly used for preventing restenosis after percutaneous coronary intervention and other catheter-based revascularization therapies.
To our surprise, the T cell cytokine IFN-␥ was paradoxically found to be a potent inhibitor of both vascular SMC differentiation and proliferation in various experimental settings including cell culture and animal models. 14 Amento and Libby demonstrated that IFN-␥-stimulated SMCs also had a reduced capacity to produce collagen fibers. 15 The combined effects of this cytokine on SMCs and collagen suggested that IFN-␥-secreting T cells might have a role in fibrous cap thinning and plaque destabilization. In our early human studies, immune staining of IFN-␥ could be detected in and around some of the lymphocytes, suggesting a paracrine secretion within the plaque. 4 In later studies, the local production of IFN-␥ by T cells in human plaques was verified by more sophisticated immunoassays and mRNA analyses, 16 altogether strengthening the evidence for a local Th1-type immune response in the plaque.
The class II molecules thus appeared to be involved in growth control, but did an aberrant expression by SMCs also imply that the cells became immunologically active? Findings by Libby et al indicated that SMCs could be involved in a cytokine cascade within the plaque. 17 They showed that vascular SMCs not only responded to proinflammatory cytokines but also started to produce these cytokines themselves as part of the response. Our finding that a subpopulation of SMCs in the plaque expressed both HLA-DR and HLA-DQ further supported an active role in cellular immunity. 18 Our current understanding is that vascular SMCs as well as endothelial cells may present their MHC molecules to T cells during alloresponses, and that endothelial cells can also present peptide antigens to specific T cells. Importantly, both cell types contribute to the inflammatory cytokine cascade of atherosclerosis.
Because atherosclerosis was shown to share several important features with autoimmune diseases, the inevitable question was raised whether a specific antigen could be identified. In 1989, Witztum and coworkers reported that oxidized low-density lipoprotein (oxLDL), which is present in lesions, triggered antibody formation. 19 A first logical step was to look for the presence of clonal T cell expansions in the plaques. Sten Stemme in our laboratory isolated and cloned T cells from human carotid lesions. When he exposed T cell clones from the plaque to potential antigens, he observed that certain clones were activated by oxLDL. 20 The response was dependent on autologous antigen-presenting cells and restricted by HLA-DR. All clones that responded to oxLDL also secreted IFN-␥ on activation. In the intensive search for an atherosclerosis-related antigen, there has been evidence for plaque-derived T cell clones with reactivity to other autoantigens like heat shock proteins and a few microbial antigens. However, during the years LDL-derived antigen has established its position as a major candidate antigen giving rise to an autoimmune response in atherosclerosis.
From the mid 1990s, more direct evidence that T cells contribute to the progression of atherosclerotic lesions came from studies on atherosclerosis-prone mice, including the apoe Ϫ/Ϫ and ldlr Ϫ/Ϫ strains. As shown by Xinghua Zhou, the atherosclerotic lesions of apoe Ϫ/Ϫ mice presented a similar picture of Th1-type immune activation as the one we had previously observed in the human plaque. The effect on atherosclerosis of immune defects was investigated by crossing scid/scid mice that lacked T and B cells with apoe Ϫ/Ϫ animals to obtain an offspring that was both hypercholesterolemic and immunodeficient. When lesions in these mice were compared with those in immunocompetent apoe Ϫ/Ϫ animals, the effect was dramatic: a 70% reduction of lesion size. 21 In the next step, wild-type donor mice were immunized with an oxidized form of LDL. Their CD4ϩ T cells were then harvested and introduced into the immunodeficient apoe/scid mice causing a dramatic increase in lesions of these animals. 22 These data provided direct evidence that the cellular immune response to modified LDL antigen plays a crucial role in atherogenesis.
During the last decade, many new studies have further advanced our knowledge of T cells in atherosclerosis. Several functionally distinct T cell subsets have been CD4ϩCD25ϩ identified, such as NKT cells that accelerate atherosclerosis when recognizing lipid antigens presented through CD1 molecules. 23 Another subset, the CD4ϩCD25ϩ ϩ regulatory T cells, exert atheroprotective effects. 24 Such regulatory T cells may suppress Th1 effector cells through production of the antiinflammatory cytokines interleukin (IL)-10 and transforming growth factor (TGF)-␤. A number of experimental studies have consistently shown that both IL-10 and TGF-␤ exert antiatherogenic effects. 25, 26 Atheroprotective immunity appears to operate through humoral as well as cellular immunity. 27 Thus, protection is paralleled by increased titers of both T cell-dependent IgG antibodies to oxLDL and natural IgM antibodies to phosphocholine. 28 Several questions remain, however, including the recruitment and role in atherogenesis of CD8ϩ T cells, a heterogenous population often reacting to viral antigens and with both cytotoxic and suppressor functions. 29, 30 Another fascinating field involves the immunomodulatory effects exerted by genetic, metabolic, and environmental factors.
The discovery of T cells in the plaque changed our view of atherosclerosis, and it is now a well-established concept that inflammation plays a key role in the disease. The course of atherosclerosis appears to be highly dependent on the type of T cell response within the arterial wall. An increased Th1 activity, not adequately counteracted by regulatory mechanisms, is associated with plaque instability and an increased risk of atherothrombotic events. Activated T cells and their products may well represent new targets for treatment as well as prevention of acute coronary syndromes. For instance, this could be achieved by blockade of soluble Th1 cytokines. Antigen-specific immunization may be another strategy to enhance the response of regulatory T cells, and vaccines are currently under development. Several recent reviews have highlighted these possibilities. [31] [32] [33] The unraveling of the role of immunity in atherosclerosis continues.
